Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity

Blockade of immune checkpoint proteins (e.g., CTLA-4, PD-1) improves overall survival in advanced melanoma; however, therapeutic benefit is limited to only a subset of patients. Because checkpoint blockade acts by “removing the brakes” on effector T cells, the efficacy of checkpoint blockade may be...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JCI Insight
Auteurs principaux: Bakhru, Pearl, Zhu, Meng-Lei, Wang, Hsing-Hui, Hong, Lee K., Khan, Imran, Mouchess, Maria, Gulati, Ajay S., Starmer, Joshua, Hou, Yafei, Sailer, David, Lee, Sandra, Zhao, Fengmin, Kirkwood, John M., Moschos, Stergios, Fong, Lawrence, Anderson, Mark S., Su, Maureen A.
Format: Artigo
Langue:Inglês
Publié: American Society for Clinical Investigation 2017
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5621898/
https://ncbi.nlm.nih.gov/pubmed/28931755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.93265
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires